The Central Protocol and Data Monitoring Office (CPDMO) within the St. Jude Comprehensive Cancer Center (SJCCC) provides centralized, administrative, regulatory and educational services to SJCCC members for the conduct of clinical trials-related activities. It is the main coordinating center for protocol development, regulatory and compliance guidance, administrative submissions, protocol registration data, and quality assurance, including monitoring. The overarching goal of the CPDMO is to provide outstanding clinical trials support to SJCCC clinical investigators by: (1) facilitating the development of high quality clinical research trials, within a standardized frame work of trial development and content, so that all appropriate institutional and Federal requirements are met prior to accruing participants;(2) maintaining a centralized submission process for institutional review and approval (CT-SRC and the IRB);(3) ensuring appropriate standards of clinical trials across the institution by encouraging consistent trial conduct and regulatory compliance through the monitoring of trials;(4) ensuring appropriate research participant enrollment via a centralized clinical trial registration system;(5) providing appropriate infrastructure and coordination for clinical trials at our affiliate and collaborating institutions;and (6) adhering to the Data Safety Monitoring Plan approved by the NCI in August 2010. In addition, the CPDMO provides administrative support to the CTSRC to ensure appropriate scientific review of all clinical trials at the SJCCC. Clinical trials are monitored commensurate with the degree of risk involved in study subject participation, as well as the size and complexity of the study. Our position is that trial monitoring and safety reporting is a shared responsibility across all members in the clinical trial process, each having different roles and responsibilities (the Institution and the Principal Investigators and study team(s), oversight committees, monitors, etc.). Particular attention is paid to monitoring investigator-initiated clinical trials, especially those for which there is no independent outside monitoring program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA021765-35
Application #
8634435
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-01
Project End
2019-02-28
Budget Start
2014-06-09
Budget End
2015-02-28
Support Year
35
Fiscal Year
2014
Total Cost
$400,512
Indirect Cost
$173,429
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Wu, Jianrong (2015) Power and sample size for randomized phase III survival trials under the Weibull model. J Biopharm Stat 25:16-28
Serinagaoglu, Yelda; Paré, Joshua; Giovannini, Marco et al. (2015) Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development. Dev Biol 398:97-109
Kimberg, Cara I; Klosky, James L; Zhang, Nan et al. (2015) Predictors of health care utilization in adult survivors of childhood cancer exposed to central nervous system-directed therapy. Cancer 121:774-82
Bhojwani, Deepa; McCarville, Mary B; Choi, John K et al. (2015) The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. Br J Haematol 168:845-53
Chamdine, Omar; Gaur, Aditya H; Broniscer, Alberto (2015) Effective treatment of cerebral mucormycosis associated with brain surgery. Pediatr Infect Dis J 34:542-3
Karol, Seth E; Coustan-Smith, Elaine; Cao, Xueyuan et al. (2015) Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. Br J Haematol 168:94-101
Chan, W K; Suwannasaen, D; Throm, R E et al. (2015) Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia 29:387-95
Gawade, Prasad L; Oeffinger, Kevin C; Sklar, Charles A et al. (2015) Lifestyle, distress, and pregnancy outcomes in the Childhood Cancer Survivor Study cohort. Am J Obstet Gynecol 212:47.e1-10
Momani, Tha'er G; Mandrell, Belinda N; Gattuso, Jami S et al. (2015) Children's perspective on health-related quality of life during active treatment for acute lymphoblastic leukemia: an advanced content analysis approach. Cancer Nurs 38:49-58
Dodd, K; Nance, S; Quezada, M et al. (2015) Tumor-derived inducible heat-shock protein 70 (HSP70) is an essential component of anti-tumor immunity. Oncogene 34:1312-22

Showing the most recent 10 out of 5513 publications